ESMO 2026

News

In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met high expectations, with a head-to-head win over Lumakras and Krazati.

News

Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.

News

Bayer's prostate cancer drug Nubeqa has reduced the risk of the disease spreading or death by 58% in patients at high risk of disease recurrence.

News

Amgen has revealed data that it hopes will move its DLL3-targeting T-cell engager Imdelltra into the first-line setting in small cell lung cancer.

News

The VOLGA trial shows that Imfinzi and Padcev could be a rival Keytruda+Padcev in perioperative treatment of muscle-invasive bladder cancer.

News

Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).